Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity

Abstract: Novo Nordisk has innovated a subcutaneous formulation of semaglutide, branded as Ozempic, which functions as a modified human glucagon-like peptide-1 (GLP-1) analogue. This formulation is tailored to address the treatment needs of individuals diagnosed with type 2 diabetes mellitus (T2DM). By providing a modified version of the naturally occurring hormone GLP-1, Ozempic offers a therapeutic approach that targets glucose metabolism and helps regulate blood sugar levels in patients with this condition. It has been endorsed as a secondary treatment for improving glycemic control in T2DM, and it is currently being investigated for its potential in combating obesity. Studies have demonstrated that semaglutide is safe for use in both adult and elderly patients with renal or hepatic conditions, requiring no adjustment in dosage. Semaglutide is a GLP-1RA drug that is used to reduce chronic obesity and the dosage used is 2.4 mg for the patients. The study highlighted the effects of the semaglutide drug on patients with obesity and T2DM. The drug exerts several adverse side effects on co-morbid patients with T2DM and obesity. Semaglutide targets the specific area of the brain (GLP-1 receptors), which is beneficial for the regulation of the appetite and helps to manage weight. Semaglutide imitates the function of incretin. The fluctuation of the blood sugar level can be controlled with semaglutide. The long-term health complications related to diabetes can be decreased with semaglutide. This study highlights the safety concerns and risk factors associated with semaglutide.